Biofourmis closes Series C funding, reels in $100m | Healthcare Asia Magazine
, Singapore

Biofourmis closes Series C funding, reels in $100m

The round was led by SoftBank Vision Fund 2, and the company plans to use the funding to accelerate global expansion.

Digital therapeutics provider Biofourmis has completed a $100m Series C financing round led by SoftBank Vision Fund 2, the company said in a press release. Existing investors such as Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI also participated in this round.

The company plans to use the fund for developing, validating and commercialising several released and unreleased digital therapeutic solutions across cardiology, respiratory, oncology and pain management, with a focus on the US and key Asian markets including China and Japan.

With completion of its funding round, the company has also announced a new organisational structure by categorising its therapeutics and health section. The new structure will enable deeper integration with clients and partners and support ongoing innovation, Biofourmis expects.
 

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!